-
-
-
-
-
-
-
ResMed (RMD) PT Raised to $321 at RBC Capital
-
-
-
-
-
-
-
JPMorgan Starts ResMed (RMD:AU) (RMD) at Overweight
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on ResMed (RMD) as U.S. Operating Environment Is Supportive
-
-
-
-
-
-
-
ResMed (RMD) Tops Q1 EPS by 3c
-
-
-
-
-
-
-
ResMed (RMD) PT Raised to $300 at RBC Capital
-
-
-
-
-
-
-
Apple (AAPL) announces hearing aid features, sleep apnea notifications for products
-
-
-
-
-
-
-
ResMed (RMD) PT Raised to $255 at RBC Capital, Citing 'Robust Growth And Tariff Exemptions'
-
432,352 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

